期刊文献+

γ射线合并丝裂霉素C对大鼠肝脏微粒体CYP2B1、CYP2E1活性影响的体外研究 被引量:2

Effect of γ-irradiation and mitomycin C (MMC) on CYP2B1 and CYP2E1 activities in rat hepatic microsomes in vitro
下载PDF
导出
摘要 研究不同剂量γ射线照射及γ射线和丝裂霉素C(MitomycinC,MMC)联合用药对雄性SD(Sprague-Dawley)大鼠肝脏微粒体中CYP2B1、CYP2E1的影响。从空白组(未经苯巴比妥诱导)和经苯巴比妥(PB)诱导组大鼠的肝脏中提出微粒体,分别进行2Gy、8Gy和16Gyγ射线单纯照射;50μmol/LMMC单纯处理;γ射线照射后加MMC联合作用,不作任何处理的作为正常对照组,然后测定CYP2B1、CYP2E1活性。实验结果显示,无论是空白组,还是PB诱导组的微粒体,在各剂量γ射线照射后,CYP2B1、CYP2E1活性变化都没有统计学差异(p>0.05);50μmol/LMMC作用后,CYP2B1活性没有明显变化(p>0.05),但使CYP2E1活性下降明显(p<0.01)。两因素析因分析发现对于微粒体中CYP2B1、CYP2E1活性,γ射线照射和MMC作用之间没有交互作用。说明在体外试验中,γ照射对大鼠肝脏微粒体CYP2B1、CYP2E1活性没有影响,50μmol/LMMC的作用对CYP2B1活性也没有影响,但可以抑制CYP2E1活性。 The purpose of this study is to evaluate activity changes of CYP2B l and CYP2E1 in male SD rat hepatic microsomes by γ-irradiation and/or MMC in vitro. The hepatic microsomes from blank control or phenobarital (PB)-induced rats were treated by^137 Cs γ-rays (2Gy, 8Gy and 16Gy), 50μmol/L MMC, or 50μmol/L MMC after the irradiation The CYP2B1 and CYP2E1 activities were determined, and were compared with the control group, which were untreated.. The results showed that the CYP2B1 and CYP2E1 activities were not changed after the irradiation in PB-induced rat liver microsomes (P〉0.05); The CYP2E1 activity decreased significantly by the MMC treatment (P〈0.01), whereas the CYP2B1 activity did not changed (P〉0.05). There was no interaction between MMC and γ-irradiation on the CYP2B1 and CYP2E1 activities. In conclusion, the present investigations indicated that the CYP2E1 activity was inhibited significantly in 50μmol/L MMC, but not in γ-irradiation in vitro. The CYP2B1 activity waS no significant changed not onlv under γ-irradiation but also MMC treatment in vitro.
出处 《辐射研究与辐射工艺学报》 CAS CSCD 北大核心 2005年第5期312-315,共4页 Journal of Radiation Research and Radiation Processing
基金 国家自然科学基金(30100042)资助
关键词 γ照射 丝裂霉素C CYP2B1 CYP2E1 γ-irradiation Mitomycin C (MMC) CYP2B1 CYP2E1
  • 相关文献

参考文献16

  • 1孙忠实,朱珠.药物代谢性相互作用研究进展[J].药物不良反应杂志,2000,2(1):6-14. 被引量:51
  • 2Palamanda J R, Casciano C N, Norton L A, et al. Drug Metab Dispos, 2001, 29(6): 863-867.
  • 3Chu I, Favreau L, Soares T, et al. Rapid Commun Mass Spectrom, 2000, 14(4): 207-214.
  • 4Bradner W T. Cancer Treat Rev, 2001, 27(1): 35-35.
  • 5Nayor M A, Thomson P. Mini Rev Med Chem, 2001,1( 1 ): 17-19.
  • 6Jaffer M, Williams K J, Stratford I J. Adv Drug Deli Rev,2001, 53(2): 217-228.
  • 7沈钧,徐佩佩,金锡鹏.肝脏中细胞色素P450测定方法的改进[J].工业卫生与职业病,1997,23(4):236-238. 被引量:25
  • 8Lee S S T, Scott J G. J Economical Entomology, 1989,82(6): 1559-1563.
  • 9Ronis M J J, Hodgson E, Dauterman W C. Pesticide Biochemistry and Physiology, 1988, 32(1): 74-90.
  • 10Bradford M M. Analytical biochemistry, 1976, 72(1-2):248-254.

二级参考文献20

  • 1金念祖,陈景衡.大鼠肝细胞色素P450含量测定的影响因素[J].中华预防医学杂志,1996,30(5):301-302. 被引量:6
  • 2前崎繁文 河野茂.抗真菌药[J].综合临床,1999,48(12):1465-1465.
  • 3Yuan R, Parmelee T, Balian JD, et al. In vitro metabolic interaction studies: Experience of the food and drug administration. Clin Pharmacol Ther, 1999, 66:9.
  • 4Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. JAMA,1998,279:1200.
  • 5Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines - Dorecent market removals mean there is a problem?JAMA, 1999, 281 : 1728.
  • 6内田英二:チトクロムP450と药物间相互作用.综合临床,1999.48:1427.
  • 7千叶宽,小林カォル.代谢过程.药局(日).1998,49:53.
  • 8Slater JW, Zechmich AD, Haxby 1313. Second-generation antihistamines. Drugs, 1999, 57:31.
  • 9Gregg CR. Drug interactions and anti - infectivetherapies. Am. J. Med, 1999, 106:227.
  • 10Mullins ME, Horowitz BZ, Linden DH, et al.Life - threatening interaction of mibefradilol and β-blockers with dihydropyridine calcium channel blockers. JAMA, 1998, 280 : 157.

共引文献71

同被引文献21

  • 1鞠美华,李燕.双环醇在大鼠和人肝微粒体的代谢[J].药学学报,2005,40(2):111-116. 被引量:16
  • 2严敏芬,郝福荣,许立明,童顺高,季华钧,沈芝芬,金一尊.3Gyγ射线照射和丝裂霉素C对大鼠肝脏细胞色素P450含量及其同工酶CYP2B1、CYP2E1活性的影响[J].辐射研究与辐射工艺学报,2005,23(4):246-250. 被引量:3
  • 3张渝娟,全钰珠,黄婉芸.吡喹酮在诱导和未诱导大鼠肝微粒体内的羟化代谢概貌及其羟化物的质谱鉴定[J].中国药理学与毒理学杂志,1996,10(1):56-61. 被引量:2
  • 4Patterson LH,Murray GL.Tumour cytochrome P450 and drug activation[J].Curr Pharm Des,2002,8(15):1335
  • 5Lockyer AE,Noble LR,Rollinson D,et al.Isolation and characterization of the full-length cDNA encoding a member of a novel cytochrome p450 family (CYP320A1) from the tropical freshwater snail,Biomphalaria glabrata,intermediate host for Schistosoma mansoni[J].Mem Inst Oswaldo Cruz,2005,100(3):259
  • 6Kivisto KT,Kroemer HK,Eichelbaum M.The role of human cytochrome P450 enzymes in the metabolism of anticancer agents:implications for drug interactions[J].Br J Clin Pharmacol,1995,40 (6):523
  • 7Xiaoming C,Ann Thomas,Yi H,et al.Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices:Correlation study with induction in vivo[J].J Pharmacol Toxicol Methods,2005,52 (2):234
  • 8Seddon B,Kelland LR,Workman P.Bioreductive prodrugs for cancer therapy[J].Methods Mol Med,2004,90:515
  • 9Mcerlane V,Yakkundi A,Mccarthy HO,et al.A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N[J].J Gene Med,2005,7 (7):851
  • 10Bradford MM.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding[J].Analytical biochemistry,1976,72 (1-2):248

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部